Pyxis Oncology, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Pyxis Oncology issued 36,047,919 common shares at $2.90/share, 1,883,121 pre-funded warrants at $2.899/warrant, and 49,310,352 common warrants at $3.50 exercise price, with Leerink Partners, Guggenheim Securities, and Wells Fargo as lead underwriters. The offering is dated September 29, 2026. Public offering price totals approximately $104.5M before underwriting discounts (~6% discount = $0.174/share).
Why this rating
Meaningful capital raise (~$98M net) for 64.4M company; materially dilutive but provides runway for biotech operations and micvotabart trial advancement.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.